Advice

following a resubmission:

ocrelizumab (Ocrevus®) is accepted for restricted use within NHSScotland.

Indication under review: The treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.

SMC restriction: Treatment of relapsing remitting multiple sclerosis (RRMS) in adults with active disease defined by clinical or imaging features who are contra-indicated or otherwise unsuitable for alemtuzumab.

Two phase III studies identified superiority of ocrelizumab when compared with another disease modifying treatment in adult patients with relapsing forms of multiple sclerosis.

SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of ocrelizumab and is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

Medicine details

Medicine name:
ocrelizumab (Ocrevus)
SMC ID:
SMC2121
Indication:
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Accepted, Restricted
Date advice published:
10 December 2018